Alfred Sandrock

Biogen Investigational Drug Shows Early Promise

Oct 11, 2016 at 02:55 pm by Staff

Boston-based biotech company Biogen had pre-clinical research and Phase 1b results for aducanumab, its investigational antibody treatment for early Alzheimer's disease, publis.... Read More